These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23136886)

  • 1. Direct AMP-activated protein kinase activators: a review of evidence from the patent literature.
    Giordanetto F; Karis D
    Expert Opin Ther Pat; 2012 Dec; 22(12):1467-77. PubMed ID: 23136886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMP-activated protein kinase modulators: a patent review (2006 - 2010).
    Yun H; Ha J
    Expert Opin Ther Pat; 2011 Jul; 21(7):983-1005. PubMed ID: 21548715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer.
    Popovics P; Frigo DE; Schally AV; Rick FG
    Expert Opin Ther Targets; 2015 May; 19(5):617-32. PubMed ID: 25600663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening methods for AMP-activated protein kinase modulators: a patent review.
    Kim J; Shin J; Ha J
    Expert Opin Ther Pat; 2015 Mar; 25(3):261-77. PubMed ID: 25535089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Targeting of AMP-Activated Protein Kinase and Opportunities for Computer-Aided Drug Design.
    Miglianico M; Nicolaes GA; Neumann D
    J Med Chem; 2016 Apr; 59(7):2879-93. PubMed ID: 26510622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential upstream regulators and downstream targets of AMP-activated kinase signaling during oocyte maturation in a marine worm.
    Stricker SA
    Reproduction; 2011 Jul; 142(1):29-39. PubMed ID: 21474604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-MET kinase inhibitors: a patent review (2011 - 2013).
    Zhu K; Kong X; Zhao D; Liang Z; Luo C
    Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promise and challenges for direct small molecule AMPK activators.
    Olivier S; Foretz M; Viollet B
    Biochem Pharmacol; 2018 Jul; 153():147-158. PubMed ID: 29408352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p21-Activated kinase inhibitors: a patent review.
    Crawford JJ; Hoeflich KP; Rudolph J
    Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.
    Cao W; Li J; Hao Q; Vadgama JV; Wu Y
    Breast Cancer Res; 2019 Feb; 21(1):29. PubMed ID: 30791936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
    Gehringer M; Muth F; Koch P; Laufer SA
    Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMPK activators--potential therapeutics for metabolic and other diseases.
    Zhou G; Sebhat IK; Zhang BB
    Acta Physiol (Oxf); 2009 May; 196(1):175-90. PubMed ID: 19245659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in the identification of adenosine monophosphate-activated protein kinase (AMPK) activators.
    Cameron KO; Kurumbail RG
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5139-5148. PubMed ID: 27727125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
    Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation.
    Salt IP; Palmer TM
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1155-67. PubMed ID: 22694351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of WO-2013040863, WO-2013041042 and WO-2013043962. Selective JAK1 inhibitors based on a 3-aminopyrazole-4-carboxamide scaffold.
    Norman P
    Expert Opin Ther Pat; 2014 Feb; 24(2):231-7. PubMed ID: 24261748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation and signaling by the AMP-activated protein kinase in endothelial cells.
    Fisslthaler B; Fleming I
    Circ Res; 2009 Jul; 105(2):114-27. PubMed ID: 19608989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rho kinase inhibitors: a patent review (2012 - 2013).
    Feng Y; LoGrasso PV
    Expert Opin Ther Pat; 2014 Mar; 24(3):295-307. PubMed ID: 24283930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.